Table 3.
Multiple-dose PK of tegaserod.
|
Treatment
(BID) |
Pharmacokinetic Parameters (mean ± SD, median for tmax) | ||||
|---|---|---|---|---|---|
|
Cmax,ss
(ng/mL) |
AUCτ
(ng*h/mL) |
tmax,ss
(h) |
Cmin,ss
(ng/mL) |
Accumulation Ratio | |
| 2 mg | 0.7 ± 0.3 | 2.4 ±1.3 | 1 | < LOQ | 0.93 |
| 6 mg | 2.7 ±1.2 | 8.9 ±4.2 | 0.8 | 0.11 ±0.07 | 1.16 |
| 12 mg (2x6 mg) | 5.6 ±2.9 | 20.4 ±14.0 | 1 | 0.28 ±0.11 | 1.15 |
Data are referred to a study involving 18 subjects (11 male and 7 female) aged 21-36 years [121].